MLTX — MoonLake Immunotherapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $2.66bn
- $2.12bn
- 38
- 31
- 52
- 35
Annual balance sheet for MoonLake Immunotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash | |||
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 8.04 | 72.1 | 511 |
| Net Total Receivables | 1.43 | 4.18 | 3.05 |
| Prepaid Expenses | |||
| Total Current Assets | 9.64 | 76.5 | 514 |
| Net Property, Plant And Equipment | 0.046 | 0.332 | 3.95 |
| Other Long Term Assets | |||
| Total Assets | 9.68 | 76.8 | 527 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 21.1 | 7.67 | 9.97 |
| Total Long Term Debt | |||
| Total Debt | |||
| Minority Interest | |||
| Total Other Liabilities | |||
| Total Funded Status | |||
| Total Liabilities | 21.3 | 27.9 | 30.9 |
| Non Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Treasury Stock | |||
| Other Equity | |||
| Total Equity | -11.6 | 48.9 | 496 |
| Total Liabilities & Shareholders' Equity | 9.68 | 76.8 | 527 |
| Total Common Shares Outstanding |